Hangzhou Alltest Biotech Balance Sheet Health
Financial Health criteria checks 6/6
Hangzhou Alltest Biotech has a total shareholder equity of CN¥3.9B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥4.2B and CN¥280.7M respectively. Hangzhou Alltest Biotech's EBIT is CN¥184.7M making its interest coverage ratio -3.9. It has cash and short-term investments of CN¥2.7B.
Key information
0%
Debt to equity ratio
CN¥0
Debt
| Interest coverage ratio | -3.9x |
| Cash | CN¥2.66b |
| Equity | CN¥3.88b |
| Total liabilities | CN¥280.73m |
| Total assets | CN¥4.16b |
Recent financial health updates
No updates
Recent updates
Hangzhou Alltest Biotech (SHSE:688606) May Have Issues Allocating Its Capital
Nov 22
Revenues Not Telling The Story For Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) After Shares Rise 27%
Oct 01Lacklustre Performance Is Driving Hangzhou Alltest Biotech Co., Ltd.'s (SHSE:688606) Low P/E
Aug 01Here's What's Concerning About Hangzhou Alltest Biotech's (SHSE:688606) Returns On Capital
Jun 08There Are Some Holes In Hangzhou Alltest Biotech's (SHSE:688606) Solid Earnings Release
May 03Optimistic Investors Push Hangzhou Alltest Biotech Co., Ltd. (SHSE:688606) Shares Up 27% But Growth Is Lacking
Apr 25Financial Position Analysis
Short Term Liabilities: 688606's short term assets (CN¥3.0B) exceed its short term liabilities (CN¥274.3M).
Long Term Liabilities: 688606's short term assets (CN¥3.0B) exceed its long term liabilities (CN¥6.4M).
Debt to Equity History and Analysis
Debt Level: 688606 is debt free.
Reducing Debt: 688606 has not had any debt for past 5 years.
Debt Coverage: 688606 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 688606 has no debt, therefore coverage of interest payments is not a concern.